|

[212Pb]Pb-MP0712 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: [212Pb]Pb-DOTAM-MAM279

Pipeline

Phase 1/2: 1

Top Sponsors

  • Molecular Partners AG1

Indications

  • Other DLL3 Expressing epNEC1
  • NEC of the Bladder1
  • Gastroenteropancreatic NEC (GEP NEC)1
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1
  • Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)1

Omaha, Nebraska1 trial

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Nebraska Cancer Specialists

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.